Systematic Review of Escalated Imatinib Doses Compared with Sunitinib or Best Supportive Care, for the Treatment of People with Unresectable/Metastatic Gastrointestinal Stromal Tumours Whose Disease has Progressed on the Standard Imatinib Dose

Jennifer Hislop, Graham Mowatt, Pawana Sharma, Cynthia Fraser, Andrew Elders, David Jenkinson, Luke Vale, Russell Petty

Research output: Contribution to journalArticle

14 Citations (Scopus)
4 Downloads (Pure)
Original languageEnglish
Pages (from-to)168-176
Number of pages9
JournalJournal of Gastrointestinal Cancer
Volume43
Issue number2
Early online date6 Oct 2011
DOIs
Publication statusPublished - Jun 2012

Keywords

  • GIST
  • gastrointestinal stromal tumours
  • unresectable
  • metastatic
  • cancer
  • imatinib
  • sunitinib
  • antineoplastic agents
  • benzamides
  • clinical trials as topic
  • disease progression
  • dose-response relationship
  • gastrointestinal stromal tumors
  • humans
  • indoles
  • piperazines
  • pyrimidines
  • pyrroles
  • treatmemnt outcome

Cite this